Systemic combination therapy of immune checkpoint inhibitors and vascular endothelial growth factors have provided the basis for improved outcomes in select patients with unresectable or metastatic hepatocellular carcinoma. However, for patients with resectable disease, surgery alone or an orthotopic liver transplant remains the standard of care. Within the realms of transplant oncology, neoadjuvant systemic therapy is currently being evaluated as a potential strategy to improve outcomes in patients with HCC. Here, we report excellent response with significant downstaging in a safe manner after neoadjuvant treatment with atezolizumab and bevacizumab in a patient diagnosed with poorly differentiated HCC. As a result of the significant response observed with safe outcomes, the patient was listed for orthotopic liver transplant (OLT) evaluation and transplanted successfully.

Original languageEnglish (US)
Article number4267
Pages (from-to)4267-4273
Number of pages7
JournalCurrent Oncology
Issue number6
StatePublished - Jun 2022


  • CTLA-4 inhibitors
  • PD-1 inhibitors
  • hepatocellular carcinoma
  • immune checkpoint inhibitors
  • immunotherapy
  • liver transplantation
  • transplant oncology

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report'. Together they form a unique fingerprint.

Cite this